FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Evan Sadler

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Genes & Molecular Sequences

Amino Acid Sequences

Phenomena

Protein Binding

Anatomy

Physiology

Mutation

Procedures

Cloning, Molecular

Co-author Network

Publications

TOP 3
J Evan Sadler
von Willebrand factor in its native environment.
Weiqiang Gao; Elodee A Tuley; Lisa A Westfield; Jian Zhu; Patricia J Anderson; J Evan Sadler
Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases.
Jing Huang; Sandra L Haberichter; J Evan Sadler
The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Evan Sadler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: J Evan Sadler
von Willebrand factor in its native environment.
Blood 2013;121(14):2583-4.
2012: Weiqiang Gao; Elodee A Tuley; Lisa A Westfield; Jian Zhu; Patricia J Anderson; J Evan Sadler
Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases.
The Journal of biological chemistry 2012;287(32):26944-52.
2012: Jing Huang; Sandra L Haberichter; J Evan Sadler
The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner.
Blood 2012;120(5):1143-9.
2012: Phillip I Tarr; Wayne L Chandler; James N George; J Evan Sadler; Han-Mou Tsai
Should all adult patients with diarrhoea-associated HUS receive plasma exchange?
Lancet 2012;379(9815):516; author reply 516-7.
2011: Fang Liu; Jing Huang; J Evan Sadler
Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways.
Blood 2011;118(12):3392-8.
2011: J Evan Sadler
Weibel-Palade bodies.
Clinical advances in hematology & oncology : H&O 2011;9(9):673-4.
2011: Luke T Dang; Ren-Huai Huang; Angie R Purvis; Lisa A Westfield; J Evan Sadler
Phylogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor.
The Journal of biological chemistry 2011;286(29):25763-9.
2011: Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; J C J Eikenboom
Functional architecture of Weibel-Palade bodies.
Blood 2011;117(19):5033-43.
2010: Jing Huang; David G Motto; David R Bundle; J Evan Sadler
Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice.
Blood 2010;116(18):3653-9.
2010: J Evan Sadler
Redeeming ristocetin.
Blood 2010;116(2):155-6.
2009: Hendrik Feys; Patricia Anderson; Karen Vanhoorelbeke; Elaine M Majerus; J Evan Sadler
Multi-step binding of ADAMTS-13 to von Willebrand factor.
Journal of thrombosis and haemostasis : JTH 2009;7(12):2088-95.
2009: Ren-Huai Huang; daved fremont; John L Diener; Robert G Schaub; J Evan Sadler
A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1.
Structure (London, England : 1993) 2009;17(11):1476-84.
2009: J Evan Sadler
von Willebrand factor assembly and secretion.
Journal of thrombosis and haemostasis : JTH 2009;7 Suppl 1():24-7.
2009: William L Nichols; Margaret E Rick; Thomas L Ortel; Robert R Montgomery; J Evan Sadler; Barbara P Yawn; Andra H James; Mae B Hultin; Marilyn J Manco-Johnson; Mark Weinstein
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.
American journal of hematology 2009;84(6):366-70.
2009: Jing Huang; Robyn Roth; John Edward Heuser; J Evan Sadler
Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress.
Blood 2009;113(7):1589-97.
2009: J Evan Sadler
Low von Willebrand factor: sometimes a risk factor and sometimes a disease.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009;():106-12.
2009: X Long Zheng; Yasunori Kitamoto; J Evan Sadler
Enteropeptidase, a type II transmembrane serine protease.
Frontiers in bioscience (Elite edition) 2009;1():242-9.
2008: Weiqiang Gao; Patricia J Anderson; J Evan Sadler
Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity.
Blood 2008;112(5):1713-9.
2008: J Evan Sadler
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Blood 2008;112(1):11-8.
2008: Takayuki Nakayama; Tadashi Matsushita; Koji Yamamoto; Noriko Mutsuga; Tetsuhito Kojima; Akira Katsumi; Norihiko Nakao; J Evan Sadler; Tomoki Naoe; Hidehiko Saito
Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis.
International journal of hematology 2008;87(4):363-70.
2008: Ren-Huai Huang; Ying Wang; Robyn Roth; Xiong Yu; Angie R Purvis; John Edward Heuser; Edward H Egelman; J Evan Sadler
Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(2):482-7.
2008: Kyuhwan Shim; Patricia Anderson; Elodee A Tuley; Erin Wiswall; J Evan Sadler
Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.
Blood 2008;111(2):651-7.
2008: X Long Zheng; J Evan Sadler
Pathogenesis of thrombotic microangiopathies.
Annual review of pathology 2008;3():249-77.
2007: Angie R Purvis; Julia Gross; Luke T Dang; Ren-Huai Huang; Milan Kapadia; R Reid Townsend; J Evan Sadler
Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(40):15647-52.
2007: Patricia Anderson; David Gailani; Hendrik Feys; Weiqiang Gao; Elaine M Majerus; Karen Vanhoorelbeke; J Evan Sadler
Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma.
Haematologica 2007;92(10):1419-22.
2007: Charles L Bennett; Benjamin Kim; Anaadriana Zakarija; Nicholas Bandarenko; Dilip K Pandey; Charlie G Buffie; June M McKoy; Amul D Tevar; John F Cursio; Paul R Yarnold; Hau C Kwaan; Davide De Masi; Ravindra Sarode; Thomas J Raife; Joseph E Kiss; Dennis W Raisch; Charles Davidson; J Evan Sadler; Thomas L Ortel; X Long Zheng; Seiji Kato; Masanori Matsumoto; Masahito Uemura; Yoshihiro Fujimura
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.
Journal of the American College of Cardiology 2007;50(12):1138-43.
2006: Weiqiang Gao; Patricia Anderson; Elaine M Majerus; Elodee A Tuley; J Evan Sadler
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(50):19099-104.
2006: J Evan Sadler; Ulrich Budde; J C J Eikenboom; Emmanuel Favaloro; Frank G H Hill; Lars Holmberg; Jørgen Ingerslev; C A Lee; D Lillicrap; P M Mannucci; Claudine Mazurier; Dominique Meyer; W L Nichols; M Nishino; Ian R Peake; Francesco Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; Augusto B Federici
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
Journal of thrombosis and haemostasis : JTH 2006;4(10):2103-14.
2006: Tatsuya Adachi; Tadashi Matsushita; Zhengyu Dong; Akira Katsumi; Takayuki Nakayama; Tetsuhito Kojima; Hidehiko Saito; J Evan Sadler; Tomoki Naoe
Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor.
Biochemical and biophysical research communications 2006;339(4):1178-83.
2006: Patricia Anderson; Koichi Kokame; J Evan Sadler
Zinc and calcium ions cooperatively modulate ADAMTS13 activity.
The Journal of biological chemistry 2006;281(2):850-7.
2006: J Evan Sadler
Thrombotic thrombocytopenic purpura: a moving target.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2006;():415-20.
2005: J Evan Sadler
von Willebrand factor: two sides of a coin.
Journal of thrombosis and haemostasis : JTH 2005;3(8):1702-9.
2005: Zhenyin Tao; Yongtao Wang; Huiwei Choi; Aubrey Bernardo; Kenji Nishio; J Evan Sadler; José A López; Jing-fei Dong
Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.
Blood 2005;106(1):141-3.
2005: Elaine M Majerus; Patricia Anderson; J Evan Sadler
Binding of ADAMTS13 to von Willebrand factor.
The Journal of biological chemistry 2005;280(23):21773-8.
2005: J Evan Sadler
New concepts in von Willebrand disease.
Annual review of medicine 2005;56():173-91.
2004: Angie R Purvis; J Evan Sadler
A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization.
The Journal of biological chemistry 2004;279(48):49982-8.
2004: J Evan Sadler
Slippery criteria for von Willebrand disease type 1.
Journal of thrombosis and haemostasis : JTH 2004;2(10):1720-3.
2004: Linda J Pike; J Evan Sadler
Proteomics, genomics and the future of medical education.
Missouri medicine 2004;101(5):496-9.
2004: Kenji Nishio; Patricia Anderson; X Long Zheng; J Evan Sadler
Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(29):10578-83.
2004: Kyuhwan Shim; Hongfa Zhu; Lisa A Westfield; J Evan Sadler
A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury.
Blood 2004;104(2):415-9.
2004: X Long Zheng; Richard M Kaufman; Lawrence T Goodnough; J Evan Sadler
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
Blood 2004;103(11):4043-9.
2004: J Evan Sadler
Medicine: K is for koagulation.
Nature 2004;427(6974):493-4.
2004: J Evan Sadler; Joel L Moake; Toshiyuki Miyata; James N George
Recent advances in thrombotic thrombocytopenic purpura.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():407-23.
2003: Elaine M Majerus; Xinglong Zheng; Elodee A Tuley; J Evan Sadler
Cleavage of the ADAMTS13 propeptide is not required for protease activity.
The Journal of biological chemistry 2003;278(47):46643-8.
2003: Nobuo Maita; Kenji Nishio; Etsuko Nishimoto; Taei Matsui; Yasuo Shikamoto; Takashi Morita; J Evan Sadler; Hiroshi Mizuno
Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins.
The Journal of biological chemistry 2003;278(39):37777-81.
2003: Xinglong Zheng; Kenji Nishio; Elaine M Majerus; J Evan Sadler
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
The Journal of biological chemistry 2003;278(32):30136-41.
2003: J Evan Sadler
Aortic stenosis, von Willebrand factor, and bleeding.
The New England journal of medicine 2003;349(4):323-5.
2003: J Evan Sadler
Structural biology. A ménage à trois in two configurations.
Science (New York, N.Y.) 2003;301(5630):177-9.
2003: J Evan Sadler
Von Willebrand disease type 1: a diagnosis in search of a disease.
Blood 2003;101(6):2089-93.
2003: Xinglong Zheng; Arnel M Pallera; Lawrence T Goodnough; J Evan Sadler; Morey A Blinder
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Annals of internal medicine 2003;138(2):105-8.
2002: J Evan Sadler
A new name in thrombosis, ADAMTS13.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11552-4.
2002: Xinglong Zheng; Elaine M Majerus; J Evan Sadler
ADAMTS13 and TTP.
Current opinion in hematology 2002;9(5):389-94.
2002: J Evan Sadler
Biomedicine. Contact--how platelets touch von Willebrand factor.
Science (New York, N.Y.) 2002;297(5584):1128-9.
2002: Takayuki Nakayama; Tadashi Matsushita; Zhengyu Dong; J Evan Sadler; Sylvie Jorieux; Claudine Mazurier; Dominique Meyer; Tetsuhito Kojima; Hidehiko Saito
Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by the CYS1272-CYS1458 disulfide bond.
The Journal of biological chemistry 2002;277(24):22063-72.
2002: Xinglong Zheng; J Evan Sadler
Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells.
The Journal of biological chemistry 2002;277(9):6858-63.
2002: John L Richardson; Pablo Fuentes-Prior; J Evan Sadler; Robert Huber; Wolfram Bode
Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor.
Biochemistry 2002;41(8):2535-42.
2002: James N George; J Evan Sadler; Bernhard Lämmle
Platelets: thrombotic thrombocytopenic purpura.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():315-34.
2002: Andreas Holzinger; Esther M Maier; Cornelius Bück; Peter U Mayerhofer; Matthias Kappler; James C Haworth; Stanley P Moroz; Hans-Beat Hadorn; J Evan Sadler; Adelbert A Roscher
Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency.
American journal of human genetics 2002;70(1):20-5.
2001: I Bodó; Akira Katsumi; Elodee A Tuley; J C J Eikenboom; Z Dong; J Evan Sadler
Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.
Blood 2001;98(10):2973-9.
2001: Xinglong Zheng; D Chung; T K Takayama; Elaine M Majerus; J Evan Sadler; K Fujikawa
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.
The Journal of biological chemistry 2001;276(44):41059-63.
2001: Joel L Moake; J Evan Sadler; P Mannucci; P Ganguly
Report on the workshop: Von Willebrand factor and Thrombotic Thrombocytopenic Purpura.
American journal of hematology 2001;68(2):122-6.
2001: Anne C Goodeve; J C J Eikenboom; David Ginsburg; Lysiane Hilbert; Claudine Mazurier; Ian R Peake; J Evan Sadler; F Rodeghiero
A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor.
Thrombosis and haemostasis 2001;85(5):929-31.
2001: CQ Li; A Vindigni; J Evan Sadler; Mark Wardell
Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin.
The Journal of biological chemistry 2001;276(9):6161-8.
2000: J L Richardson; B Kröger; W Hoeffken; J Evan Sadler; P Pereira; Robert Huber; Wolfram Bode; Pablo Fuentes-Prior
Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor.
The EMBO journal 2000;19(21):5650-60.
2000: Akira Katsumi; Elodee A Tuley; I Bodó; J Evan Sadler
Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor.
The Journal of biological chemistry 2000;275(33):25585-94.
2000: J Evan Sadler; P M Mannucci; E Berntorp; N Bochkov; V Boulyjenkov; David Ginsburg; D Meyer; Ian R Peake; F Rodeghiero; A Srivastava
Impact, diagnosis and treatment of von Willebrand disease.
Thrombosis and haemostasis 2000;84(2):160-74.
2000: T Matsushita; D Meyer; J Evan Sadler
Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis.
The Journal of biological chemistry 2000;275(15):11044-9.
2000: S Miura; CQ Li; Z Cao; H Wang; Mark Wardell; J Evan Sadler
Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion.
The Journal of biological chemistry 2000;275(11):7539-46.
1999: D Lu; Klaus Fütterer; Sergey V Korolev; X Zheng; K Tan; Gabriel Waksman; J Evan Sadler
Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide.
Journal of molecular biology 1999;292(2):361-73.
1998: J Xue; Q Wu; L A Westfield; Elodee A Tuley; D Lu; Q Zhang; K Shim; Xinglong Zheng; J Evan Sadler
Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(13):7603-7.
1998: Koichi Kokame; X Zheng; J Evan Sadler
Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.
The Journal of biological chemistry 1998;273(20):12135-9.
1998: X Yuan; X Zheng; D Lu; D C Rubin; C Y Pung; J Evan Sadler
Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development.
The American journal of physiology 1998;274(2 Pt 1):G342-9.
1998: J Evan Sadler
Biochemistry and genetics of von Willebrand factor.
Annual review of biochemistry 1998;67():395-424.
1997: D Lu; X Yuan; X Zheng; J Evan Sadler
Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain.
The Journal of biological chemistry 1997;272(50):31293-300.
1997: J Evan Sadler
Thrombomodulin structure and function.
Thrombosis and haemostasis 1997;78(1):392-5.
1996: J C Eikenboom; T Matsushita; P H Reitsma; E A Tuley; G Castaman; E Briët; J Evan Sadler
Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
Blood 1996;88(7):2433-41.
1996: J Xue; N A Jenkins; D J Gilbert; N G Copeland; J Evan Sadler
Structure and localization of the thrombin receptor gene on mouse chromosome 13.
Mammalian genome : official journal of the International Mammalian Genome Society 1996;7(8):625-6.
1996: T Englender; A Lattuada; P M Mannucci; J Evan Sadler; Aida Inbal
Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics.
Blood 1996;87(7):2788-94.
1995: J Evan Sadler; T Matsushita; Z Dong; E A Tuley; L A Westfield
Molecular mechanism and classification of von Willebrand disease.
Thrombosis and haemostasis 1995;74(1):161-6.
1995: T Matsushita; J Evan Sadler
Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
The Journal of biological chemistry 1995;270(22):13406-14.
1995: Y Kitamoto; Rosalie A Veile; H Donis-Keller; J Evan Sadler
cDNA sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen.
Biochemistry 1995;34(14):4562-8.
1995: Aida Inbal; Nurit Kornbrot; P M Mannucci; J Evan Sadler
Very low frequency of "normandy type" mutations among type 1 von Willebrand disease families.
Thrombosis and haemostasis 1995;73(2):324.
1994: J P Sheehan; D M Tollefsen; J Evan Sadler
Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
The Journal of biological chemistry 1994;269(52):32747-51.
1994: T Matsushita; Z Dong; J Evan Sadler
von Willebrand's factor and von Willebrand's disease.
Current opinion in hematology 1994;1(5):362-8.
1994: Y Kitamoto; X Yuan; Q Wu; D W McCourt; J Evan Sadler
Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(16):7588-92.
1994: J Evan Sadler; H R Gralnick
Commentary: a new classification for von Willebrand disease.
Blood 1994;84(3):676-9.
1994: david mancuso; E A Tuley; R Castillo; N de Bosch; P M Mannucci; J Evan Sadler
Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors.
Thrombosis and haemostasis 1994;72(2):180-5.
1994: J P Sheehan; J Evan Sadler
Molecular mapping of the heparin-binding exosite of thrombin.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(12):5518-22.
1994: Z Dong; R S Thoma; D L Crimmins; D W McCourt; E A Tuley; J Evan Sadler
Disulfide bonds required to assemble functional von Willebrand factor multimers.
The Journal of biological chemistry 1994;269(9):6753-8.
1994: Q Wu; V Picard; M Aiach; J Evan Sadler
Activation-induced exposure of the thrombin anion-binding exosite. Interactions of recombinant mutant prothrombins with thrombomodulin and a thrombin exosite-specific antibody.
The Journal of biological chemistry 1994;269(5):3725-30.
1993: Aida Inbal; Nurit Kornbrot; P Harrison; A M Randi; J Evan Sadler
Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor.
Thrombosis and haemostasis 1993;70(6):1058-62.
1993: I Rabinowitz; A M Randi; Kenneth Shindler; E A Tuley; P K Rustagi; J Evan Sadler
Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
The Journal of biological chemistry 1993;268(27):20497-501.
1993: Aida Inbal; T Englender; Nurit Kornbrot; A M Randi; G Castaman; P M Mannucci; J Evan Sadler
Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method.
Blood 1993;82(3):830-6.
1993: M R Ledford; I Rabinowitz; J Evan Sadler; J W Kent; Francisco Civantos
New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami.
Blood 1993;82(1):169-75.
1993: J Evan Sadler; S R Lentz; J P Sheehan; M Tsiang; Q Wu
Structure-function relationships of the thrombin-thrombomodulin interaction.
Haemostasis 1993;23 Suppl 1():183-93.
1993: J P Sheehan; Q Wu; D M Tollefsen; J Evan Sadler
Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
The Journal of biological chemistry 1993;268(5):3639-45.
1993: David Ginsburg; J Evan Sadler
von Willebrand disease: a database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Thrombosis and haemostasis 1993;69(2):177-84.
1993: S R Lentz; J Evan Sadler
Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum.
Blood 1993;81(3):683-9.
1993: S M Ahern; T Miyata; J Evan Sadler
Regulation of human tissue factor expression by mRNA turnover.
The Journal of biological chemistry 1993;268(3):2154-9.
1992: Q Wu; M Tsiang; J Evan Sadler
Localization of the single-stranded DNA binding site in the thrombin anion-binding exosite.
The Journal of biological chemistry 1992;267(34):24408-12.
1992: I Rabinowitz; E A Tuley; david mancuso; A M Randi; B G Firkin; M A Howard; J Evan Sadler
von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(20):9846-9.
1992: A M Randi; Sylvie Jorieux; E A Tuley; Claudine Mazurier; J Evan Sadler
Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
The Journal of biological chemistry 1992;267(29):21187-92.
1992: Aida Inbal; Uri Seligsohn; Nurit Kornbrot; B Brenner; P Harrison; A Randi; I Rabinowitz; J Evan Sadler
Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families.
Thrombosis and haemostasis 1992;67(6):618-22.
1992: Q Wu; M Tsiang; S R Lentz; J Evan Sadler
Ligand specificity of human thrombomodulin. Equilibrium binding of human thrombin, meizothrombin, and factor Xa to recombinant thrombomodulin.
The Journal of biological chemistry 1992;267(10):7083-8.
1992: M Tsiang; S R Lentz; J Evan Sadler
Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity.
The Journal of biological chemistry 1992;267(9):6164-70.
1992: Sylvie Jorieux; E A Tuley; Christine Gaucher; Claudine Mazurier; J Evan Sadler
The mutation Arg (53)----Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor.
Blood 1992;79(3):563-7.
1991: J Evan Sadler
von Willebrand factor.
The Journal of biological chemistry 1991;266(34):22777-80.
1991: Q Y Wu; J P Sheehan; M Tsiang; S R Lentz; Jens Birktoft; J Evan Sadler
Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(15):6775-9.
1991: E A Tuley; Christine Gaucher; Sylvie Jorieux; N K Worrall; J Evan Sadler; Claudine Mazurier
Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(14):6377-81.
1991: A M Randi; I Rabinowitz; david mancuso; P M Mannucci; J Evan Sadler
Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.
The Journal of clinical investigation 1991;87(4):1220-6.
1991: S R Lentz; M Tsiang; J Evan Sadler
Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms.
Blood 1991;77(3):542-50.
1991: david mancuso; E A Tuley; L A Westfield; T L Lester-Mancuso; M M Le Beau; J M Sorace; J Evan Sadler
Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction.
Biochemistry 1991;30(1):253-69.
1991: J Evan Sadler; david mancuso; A M Randi; E A Tuley; L A Westfield
Molecular biology of von Willebrand factor.
Annals of the New York Academy of Sciences 1991;614():114-24.
1990: M Tsiang; S R Lentz; W A Dittman; D Wen; E M Scarpati; J Evan Sadler
Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues.
Biochemistry 1990;29(47):10602-12.
1990: I R Peake; D Bowen; P Bignell; M B Liddell; J Evan Sadler; G Standen; A L Bloom
Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene.
Blood 1990;76(3):555-61.
1990: I R Peake; M B Liddell; P Moodie; G Standen; david mancuso; E A Tuley; L A Westfield; J M Sorace; J Evan Sadler; C L Verweij
Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual.
Blood 1990;75(3):654-61.
1989: E M Scarpati; J Evan Sadler
Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.
The Journal of biological chemistry 1989;264(34):20705-13.
1989: david mancuso; E A Tuley; L A Westfield; N K Worrall; B B Shelton-Inloes; J M Sorace; Y G Alevy; J Evan Sadler
Structure of the gene for human von Willebrand factor.
The Journal of biological chemistry 1989;264(33):19514-27.
1989: G A Silverman; Richard D Ye; K M Pollock; J Evan Sadler; Stanley J Korsmeyer
Use of yeast artificial chromosome clones for mapping and walking within human chromosome segment 18q21.3.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(19):7485-9.
1989: Richard D Ye; S M Ahern; M M Le Beau; R V Lebo; J Evan Sadler
Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin.
The Journal of biological chemistry 1989;264(10):5495-502.
1988: W A Dittman; T Kumada; J Evan Sadler; Philip W Majerus
The structure and function of mouse thrombomodulin. Phorbol myristate acetate stimulates degradation and synthesis of thrombomodulin without affecting mRNA levels in hemangioma cells.
The Journal of biological chemistry 1988;263(30):15815-22.
1988: Richard D Ye; T C Wun; J Evan Sadler
Mammalian protein secretion without signal peptide removal. Biosynthesis of plasminogen activator inhibitor-2 in U-937 cells.
The Journal of biological chemistry 1988;263(10):4869-75.
1987: E M Scarpati; J Evan Sadler; P O'Connell; Y Nakamura; M Leppert; L Ballard; G M Lathrop; J M Lalouel; Raymond White
Identification and mapping of RFLPs for human tissue factor (HTF) to chromosome 1p.
Nucleic acids research 1987;15(21):9098.
1987: E M Scarpati; D Wen; G J Broze; J P Miletich; R R Flandermeyer; N R Siegel; J Evan Sadler
Human tissue factor: cDNA sequence and chromosome localization of the gene.
Biochemistry 1987;26(17):5234-8.
1987: D Z Wen; W A Dittman; Richard D Ye; L L Deaven; Philip W Majerus; J Evan Sadler
Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene.
Biochemistry 1987;26(14):4350-7.
1987: B B Shelton-Inloes; F F Chehab; P M Mannucci; A B Federici; J Evan Sadler
Gene deletions correlate with the development of alloantibodies in von Willebrand disease.
The Journal of clinical investigation 1987;79(5):1459-65.
1987: Richard D Ye; T C Wun; J Evan Sadler
cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta.
The Journal of biological chemistry 1987;262(8):3718-25.
1986: B B Shelton-Inloes; K Titani; J Evan Sadler
cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms.
Biochemistry 1986;25(11):3164-71.
1986: J Evan Sadler; B B Shelton-Inloes; J M Sorace; K Titani
Cloning of cDNA and genomic DNA for human von Willebrand factor.
Cold Spring Harbor symposia on quantitative biology 1986;51 Pt 1():515-23.
1985: J Evan Sadler; B B Shelton-Inloes; J M Sorace; J M Harlan; K Titani; E W Davie
Cloning and characterization of two cDNAs coding for human von Willebrand factor.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(19):6394-8.